Rhythm obesity drug wins broader use from FDA [Yahoo! Finance]
Rhythm Pharmaceuticals, Inc. (RYTM)
Last rhythm pharmaceuticals, inc. earnings: 3/8 08:12 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.rhythmtx.com
Company Research
Source: Yahoo! Finance
The Food and Drug Administration has widened use of a drug for rare forms of obesity in a decision that could significantly strengthen the sales outlook for its developer, Rhythm Pharmaceuticals. The FDA on Friday cleared use of Imcivree , a one-daily injection, for adults and children at least 4 years of age with a type of obesity driven by injury to the hypothalamic region of the brain. In clinical testing, Rhythm's drug helped people with this “acquired hypothalamic obesity” lose about 18 percentage points more of their body weight than placebo recipients. It's now the first medication available for the condition. “This is a transformative milestone for Rhythm and reinforces our commitment to bringing meaningful therapies to patients living with rare MC4R pathway diseases,” said Rhythm CEO David Meeker in a statement, referring to the biological pathway Imcivree acts on. The clearance marks a step forward for a company whose value has more than quintupled since going public
Show less
Read more
Impact Snapshot
Event Time:
RYTM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RYTM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RYTM alerts
High impacting Rhythm Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
RYTM
News
- How Investors May Respond To Rhythm Pharmaceuticals (RYTM) FDA Win For IMCIVREE In Acquired Hypothalamic Obesity [Yahoo! Finance]Yahoo! Finance
- Rhythm Pharmaceuticals Wins FDA Approval for IMCIVREE in Acquired Hypothalamic Obesity Launch [Yahoo! Finance]Yahoo! Finance
- Rhythm Pharmaceuticals EMANATE Phase 3 Misses Primary Endpoint, Sees Subgroup Signals for Setmelanotide [Yahoo! Finance]Yahoo! Finance
- PANTHERx® Rare Selected by Rhythm Pharmaceuticals Inc. as the Exclusive U.S. Specialty Pharmacy for the Expanded Indication for IMCIVREE® (setmelanotide)PR Newswire
- Rhythm Pharmaceuticals (RYTM) Reports Phase 3 EMANATE Trial Topline Results for Setmelanotide [Yahoo! Finance]Yahoo! Finance
RYTM
Earnings
- 2/26/26 - Beat
RYTM
Sec Filings
- 3/20/26 - Form 8-K
- 3/16/26 - Form 8-K
- 3/16/26 - Form 4
- RYTM's page on the SEC website